iGii Enters New Era with Prymexa Partnership
Deal News | Nov 06, 2024 | Par Equity LLP
iGii, a portfolio company of Par Equity LLP, has formed a significant multi-million-pound partnership with Prymexa to develop a novel toolkit for diagnosing perimenopause. This collaboration aims to fill the considerable gap in women's health information, specifically concerning perimenopause and menopause, which currently leaves 60% of women under 40 insufficiently informed. The partnership underscores an essential step towards enhancing healthcare access and the quality of diagnostics for women's health. This venture is expected to significantly influence women's healthcare by providing better diagnostics, reflecting iGii's ongoing success and its potential impact in the field.
Sectors
- Healthcare
- Private Equity
Geography
- United Kingdom – Par Equity LLP and iGii are likely based in the UK, given the use of 'pound' in the financials and typical locality of the firm.
Industry
- Healthcare – The article discusses a partnership creating diagnostic tools for women's health, particularly around perimenopause and menopause.
- Private Equity – Par Equity LLP, a private equity firm, is involved through its portfolio company, iGii.
Financials
- Multi-million pounds – The partnership between iGii and Prymexa is described as a multi-million-pound collaboration.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| iGii | Portfolio Company | Company | A company focused on creating diagnostic tools for women's health, specifically perimenopause. |
| Par Equity LLP | Private Equity Firm | Company | A private equity firm supporting iGii in its innovative healthcare ventures. |
| Prymexa | Collaboration Partner | Company | Partnered with iGii to develop an innovative toolkit for perimenopause diagnostics. |